Innate Pharma, Inc.

Innate Pharma's IPH6501, a tetraspecific NK cell engager targeting CD20 B cells for Non-Hodgkin Lymphoma, will be featured at the European Hematology Association Congress in June 2025.

CD39-targeted therapies are emerging as a promising strategy to modulate immune responses in various diseases by influencing the purinergic signaling pathway.

Innate Pharma has initiated a Phase 1 clinical trial (NCT06781983) to evaluate the safety and tolerability of IPH4502 in patients with advanced solid tumors expressing Nectin-4.

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) have entered into an agreement to clinically study IPH6501 in follicular lymphoma.

• Bullous pemphigoid (BP), a subepidermal autoimmune blistering disease primarily affecting the elderly, currently lacks approved therapies in the United States, creating a significant unmet need. • The BP treatment landscape is dominated by off-label corticosteroids and immunosuppressants, highlighting the urgent need for targeted and approved therapies to improve patient outcomes. • Several therapies are in advanced Phase III clinical development, including AstraZeneca's Fasenra, Sanofi/Regeneron's Dupixent, and Akari Therapeutics' nomacopan, signaling potential paradigm shift. • The influx of pipeline therapies aims to address unmet needs, such as diagnostic biomarkers and vulnerable patient population, and could reshape the market dynamics in bullous pemphigoid.

Innate Pharma received FDA clearance for its IND application for IPH4502, an antibody-drug conjugate targeting Nectin-4 in solid tumors.

Innate Pharma reported positive Phase 2 results for lacutamab in mycosis fungoides, engaging with the FDA for potential accelerated approval.

Interim results from the NeoCOAST-2 Phase 2 trial show monalizumab, combined with durvalumab and chemotherapy, demonstrates encouraging clinical outcomes in early-stage NSCLC.